Seelos Therapeutics shares soar on acquisition of Parkinson's candidate license created at UCLA
Seelos Therapeutics Inc (NASDAQ:SEEL) CEO Dr. Raj Mehra tells Proactive Investors the company has acquired an exclusive license to the rights to a potential Parkinson’s disease therapy created by researchers at the University of California, Los Angeles.
Mehra said the therapy, known as SLS-007, may slow the progression of Parkinson's disease. He said the company may soon perform studies in mice.
Shares of the New York-based biotech rose more than 40% on Friday.